Mutants of Candida albicans hypersensitive to calcofluor white display susceptibility to antifungal drugs
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antifungální látky farmakologie MeSH
- buněčná stěna účinky léků genetika MeSH
- Candida albicans účinky léků genetika MeSH
- echinokandiny farmakologie MeSH
- kaspofungin MeSH
- lipopeptidy MeSH
- mikrobiální testy citlivosti MeSH
- mutace MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antifungální látky MeSH
- echinokandiny MeSH
- kaspofungin MeSH
- lipopeptidy MeSH
An increased infection incidence of Candida albicans (most common human fungal pathogen) contributes to the need of further functional genetic studies and development of new antifungal drugs. We developed a method to create mutants of C. albicans using an antisense cDNA library to interfere with gene expression, followed by screening for hypersensitivity to Calcofluor White (CFW) and the antifungal drugs caspofungin and itraconazole. Mutants with these properties have with a high probability defects in cell-wall integrity. Fifty out of 200 transformant colonies analyzed (25%) showed hypersensitivity to CFW compared with the parental strain C. albicans CAI-4. Most of those CFW-hypersensitive mutants further displayed the susceptibility to antifungal drugs itraconazole and caspofungin using microbroth dilution method M27-A and an agar-diffusion test. The mutants obtained through this procedure could provide a potential model for screening antifungal pro-drugs which show weak action when standard C. albicans strain is used and may also aid in further identifying genes involved in cell integrity. In addition, we describe the effect of varying several parameters in electroporation transformation, including treatment with lithium acetate, upon the efficiency of transformation in C. albicans.
Zobrazit více v PubMed
J Biol Chem. 2000 May 19;275(20):14882-9 PubMed
Antimicrob Agents Chemother. 2000 Feb;44(2):368-77 PubMed
Fungal Genet Biol. 2005 Feb;42(2):165-77 PubMed
Yeast. 2007 Apr;24(4):239-52 PubMed
Nat Genet. 1999 Mar;21(3):245-6 PubMed
Clin Infect Dis. 2006 Apr 15;42(8):1171-8 PubMed
Nat Protoc. 2006;1(5):2253-6 PubMed
J Bacteriol. 1997 Jan;179(2):463-9 PubMed
Biochim Biophys Acta. 1999 Jan 6;1426(2):373-83 PubMed
Folia Microbiol (Praha). 2007;52(3):297-312 PubMed
Genetics. 1997 Oct;147(2):435-50 PubMed
J Exp Med. 2005 Sep 5;202(5):597-606 PubMed
J Biochem. 1967 Aug;62(2):276-8 PubMed
Yeast. 1998 Apr 30;14(6):565-71 PubMed
J Bacteriol. 1998 Mar;180(6):1418-24 PubMed
Antimicrob Agents Chemother. 1999 Jun;43(6):1383-6 PubMed
Clin Microbiol Rev. 2007 Jan;20(1):133-63 PubMed
Nat Biotechnol. 2001 Mar;19(3):235-41 PubMed
Yeast. 2004 Apr 15;21(5):413-27 PubMed
Antimicrob Agents Chemother. 2006 Jun;50(6):2058-63 PubMed
Curr Genet. 2003 Mar;42(6):339-43 PubMed
J Biol Chem. 2006 Dec 29;281(52):40399-411 PubMed
Annu Rev Genet. 2007;41:193-211 PubMed
Mol Microbiol. 2002 May;44(3):841-53 PubMed
Antimicrob Agents Chemother. 1996 Oct;40(10):2300-5 PubMed
Antimicrob Agents Chemother. 2002 Jun;46(6):1688-94 PubMed
Mycologia. 2006 May-Jun;98(3):399-409 PubMed
Yeast. 1999 Nov;15(15):1609-18 PubMed
Fungal Genet Biol. 2008 Oct;45(10):1404-14 PubMed
Folia Microbiol (Praha). 2007;52(1):39-43 PubMed
Mol Microbiol. 1992 Dec;6(23):3567-74 PubMed
